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Introduction
•
•

•

The optimal 1st treatment of pediatric breast abscesses has
been questioned
We previously reported treatment and outcomes of
children with untreated, not spontaneously draining (UTND)
breast abscesses (Dekonenko et al J Surg Res 2021).
•
Trial of antibiotics can first be considered, no
impact of first treatment on persistence rate
Led us to question: is disease persistence impacted by
treatment at a pediatric tertiary referral center?

Methods
•
•
•
•

Single-institution, retrospective review
Patients <18 years old with breast abscess
Stratified by UTND or previously treated, not spontaneously
draining (PTND)
Primary outcome: persistent disease requiring further
treatment

Results
•

•

•

•

114 patients met inclusion criteria
•
96 UTND
•
18 PTND
Patients 1 st treated at outside hospitals (OSH) were more
likely to use antibiotics alone as primary therapy (100% vs.
47%, p=<0.001)
•
Persistent disease more common in those treated
with abx 1 st at OSH vs. abx 1 st at CMH
11/18 children treated first at OSH required treatment for
persistent disease (73% needle aspiration, 27% incision and
drainage)
TMP-SMX used most at OSH (50%) vs. Clindamycin at CMH
(71%, p=<0.01)

114 children with
breast abscesses

Treatment at CMH
Treatment at outside hospital

18 previously
treatment, not
draining

96 untreated, not
draining

45 (47%) treated
with antibiotics
alone

26 (27%) treated
with needle
aspiration

25 (26%) treated
with I&D
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with antibiotics
alone
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therapy

2 had persistent
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escalation of
therapy

1 had persistent
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therapy
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Figure 1. Clinical course, initial treatment, and need for escalation of therapy (if
applicable) in children with breast abscesses
I&D = incision & drainage
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Conclusion
Antibiotic therapy, when properly chosen, remains a safe first-line treatment of pediatric breast abscesses.

